Miromatrix Medical Inc. (NASDAQ:MIRO – Get Rating) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 375,500 shares, an increase of 2,083.1% from the March 15th total of 17,200 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average trading volume of 120,900 shares, the short-interest ratio is currently 3.1 days.
Shares of NASDAQ MIRO traded up $0.12 during trading on Tuesday, reaching $3.84. The company had a trading volume of 5 shares, compared to its average volume of 318,448. Miromatrix Medical has a 52 week low of $2.02 and a 52 week high of $16.52. The company has a current ratio of 12.13, a quick ratio of 12.12 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $3.54.
Miromatrix Medical (NASDAQ:MIRO – Get Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.12).
Miromatrix Medical Company Profile (Get Rating)
Miromatrix Medical Inc engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them.
- Get a free copy of the StockNews.com research report on Miromatrix Medical (MIRO)
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- Tilray Stock Has Better Days Ahead
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.